bioqore

Eliminating the manufacturing bottleneck in drug development.

The only lab-validated AI platform for biomanufacturing.

josh@bioqore.ai

brendan@bioqore.ai

bioqore.ai

bioqore

We're already in market.

Momentum

$2,000,000	**Recognized revenue** Received from completed programs
$6,500,000	**Contracted Revenue** Signed multi-year MSAs with enterprise pharma
$9,200,000	**Total Contract Value** Full contract value across all active agreements
7 days*	**Sample to Result** vs 6–12 weeks at legacy CDMOs
30x*	**Cheaper than CDMOs** At equivalent throughput

Treatments that could save lives — saved by infrastructure.

Bioqore is building the operating system for biological manufacturing.

* Pipeline assumptions.

bioqore

Drug development is stalled in a pre-AI infrastructure.

Not in trials, but in manufacturing.

The problem

of programs fail before commercial scale.
Not bad science. Bad infrastructure.

The bottleneck isn't the science. It's the infrastructure around it. Traditional Contract Development and Manufacturing Organizations (CDMOs), entrusted to scale up drug manufacturing for clinical trials are slow, expensive, and built for a pre-AI world.

Digital-only platforms lack physical validation, offering predictions without proof — only half the solution.

The result: Biotech companies burn years and millions before their drug ever reaches a patient, if it reaches one at all.

bioqore

Every year, hundreds of drug programs die.

The manufacturing bottleneck kills programs, not the science.

The cost of inaction

2-5 years

CMC Development Timeline
Each manufacturing program takes years before a single clinical trial begins. 90% of programs fail before commercial scale, often due to manufacturing variability.

$5-10M+

Cost Per CMC Program
Biotechs burn millions outsourcing to traditional CDMOs before a drug ever reaches trial. Cash-strapped companies run out of runway waiting. (Deloitte, 2024)

60%

Phase III Manufacturing Failures
60% of Phase III trials fail due to manufacturing variability and scale-up failures. Each failure costs $100M+ and 2–3 years of runway lost.

bioqore

A real company.
A program about to die.

This isn't hypothetical. This is what the problem looks like on the ground.

Real story

A clinical-stage biotech

Spent $2M+ and 18 months trying to scale their biologic with a large-scale CDMO — with nothing to show for it.

Their program lead was under pressure. The next funding round required hitting a critical clinical milestone on time.

Traditional CDMOs quoted 2–5 years. Their lead program was at risk of shutting down.

bioqore®

Bioqore delivered validated manufacturing data in under 2 weeks for $150K.

5-8x

Yield improvement
Typical range per program

$150K

Cost
vs $2M+ with legacy CDMOs

1-2 Weeks

Timeline
vs. 18 months burned

bioqore

Four forces are converging. Right now.

Government mandates and capital are reshoring biomanufacturing. Investors who move now will capture the wave before it’s priced in.

Why now

01

US Biomanufacturing Mandate
Sept 2022 EO mandated domestic biotech scale-up. BioMADE, ARPA-H & Mission Genesis deploying billions. 70%+ of US biologics still manufactured offshore. Bioqore is BIOSECURE-compliant and US-built.

02

AI + Lab Convergence
Closed-loop AI-to-lab systems are now viable at low cost. Bioqore's full platform runs on <$1M in hardware and scales linearly.

03

FDA Digital Guidance
New FDA digital process control guidance accelerates AI adoption in CMC. Early movers with standardized data packages will own the standard.

04

Biosimilar Wave
$200B+ in biologics losing patent protection through 2030. Each biosimilar program needs CMC development. Bioqore's licensing option ($10–20M/asset) captures this wave.

bioqore

AI models that predict, validate, and learn from experimental data

Bioqore combines proprietary Bayesian AI with $1M+ in micro-scale lab automation to deliver results no other company can. A client sends a sample. Our AI predicts optimal conditions. Our lab validates physically. Actionable results arrive in 7 days.

The solution

Not GPT-based. Proprietary Bayesian architecture.

Physical proof, not just software predictions.

Every engagement trains the shared predictive model.

US-built. BIOSECURE Act compliant.

bioqore

A frictionless handoff. Actionable data in 7 days to 1 month.*

Zero workflow changes for the client. AI predicts. Lab validates. You receive actionable data.

Our solution

Harmonize
AI harmonizes your prior biomanufacturing data and maps the full design space. Proprietary Bayesian models. Not GPT. Not guessing.



Validate
Physical lab experimentally validates predictions. $1M micro-scale automation executes experiments. Physical proof, not software simulations.

1 **You provide**
Drug candidate shipped under MTA. Your manufacturing goals, operational boundaries, and data from prior experiments

Predict
Predictive modeling optimizes production parameters and identifies unexplored process space. 95% confidence intervals, not single-point estimates.

3 **We deliver**
FDA-compatible data package. Standardized protocols designed to meet your goals. Clients retain full ownership of their data, ready for submission and scale with confidence.

bioqore

Bioqore’s Bayesian models trained on proprietary bioprocess data.

Not GPT-based. Not pure SaaS.
Physical proof + digital intelligence

Technology

Bioprocess Risk Modeling

3mL to 80,000L

Simulates bioprocess performance at every scale from bench to commercial. Outputs a 95% confidence range, not just a single optimal point. Proprietary architecture protected as trade secret.

- Risk-aware recommendations across the full scale range
- Robust parameter ranges, not single-point optima
- Reduces manufacturing failure risk at every stage by design.

Network Effect Flywheel

Compounds with every program

Each client engagement adds validated, real-world bioprocess data to our foundational model. More programs = better predictions = stronger moat. Network effects grow with every engagement.

- More engagements = better model accuracy
- Data moat is defensible and non-replicable
- Licensing potential grows with data scale

bioqore

Two half-solutions.
We are making them whole.

The market has tools, but not a complete system.
No other company closes the full loop.

Advantages

	Bioqore AI prediction + physical validation	**Digital-Only SaaS** Benchling, Scispot	**Traditional CDMOs** Lonza, Catalent, Samsung Bio
Fast to deploy	✓ 20–30x faster	✓ Yes	⊘ No, 2-5 years
Physical wet lab	✓ 7 days	— No	✓ Yes
Lab validation	✓ Physical proof	— No	✓ Yes
Data management	✓ Closed-loop	✓ Yes	— No
Regulatory track record	✓ FDA-compatible	— No	✓ Yes
AI optimization	✓ Bayesian, 95% CI	⊘ Yes, but black box	— No
Affordable	✓ 30x cheaper	— No	⊘ No, $5–10M+
BIOSECURE / domestic	✓ US-built	— No	⊘ No, offshore
Closed-loop learning	✓ Yes	— No	— No

bioqore

Revenue today. A clear path to $50M+. Up to 80% gross margins throughout.

Business model

How a client relationship grows

Land
$150K–600K First project (case study)

Convert
Subscription Models running in client environment Recurring revenue + ongoing data

Expand
$4.6–5.3M ACV Multi-molecule expansion 24-mo contracts

License
$10–20M/asset Per molecule Recurring

ARR Projection



bioqore

Bioqore's growth roadmap. One compounding moat.

Each phase funds and enables the next. Designed to be capital-efficient.

Path to scale

Case Study Factory
$2M Quality ARR

- Close 5–10 programs at $100–500K each
- Publish pharma-grade case studies for BD
- Scale lab operations and build gold-standard data library
- Lock in 2–3 multi-year enterprise accounts

Platform + License
$15M ARR

- Launch SaaS platform layer on top of lab-validated data moat
- First licensing deal with mid-size pharma
- Expand to 3 additional molecule classes
- Land FDA pilot program partnership

Category Ownership
$50M+ ARR

- De facto standard for biologic CMC in the US
- Multi-asset licensing ($10–20M per asset)
- Regulatory data package as competitive moat
- International expansion: EU, APAC

0 | 6 | 12 | 18 | 24 | 30 | 36+ mo.

bioqore

The people building Bioqore.

The team

Joshua Hinckley, PhD
PhD — CEO & Co-Founder

PhD Chemistry, Cornell. Postdoc MIT + Broad Institute. 45+ publications, 15+ patents. Pfizer, Novartis, Sartorius collaborations.

Brendan Dang
COO & Co-Founder

UC Berkeley + Broad Institute. Fifty Year VC 5050 Fellow, Z-Fellow. AI-driven ops and enterprise deployment in biomanufacturing.



Tim Lorgeree
CTO

MS CS + MS Chemistry. 4+ yrs MIT Technical Associate. ML, Bayesian inference, bioprocess automation.

Jess Bryant
Director of the Lab

PhD Biological Oceanography, MIT. 7+ yrs Discovery Analytics at Seres Therapeutics. Computational biology, multi-omics.

Linda Phelan Dyson
MPH, Pharma Commercial & Enterprise Advisor

30+ yrs pharma commercial strategy. Pfizer, Roche/Genentech.

Caleb DesRosiers
JD, MPA, Pharma Strategy & Market Access Advisor

25+ yrs pharma policy & market access. Pfizer, Roche. Board Director, Daxor Corp (Nasdaq).

bioqore

Raising to hire world-class talent and execute on contracted multi-year programs.

Bioqore has signed $6M+ in contracted value and 5 multi-year MSAs with enterprise pharma—programs that are ready to execute. The bottleneck today isn't demand; it's delivery capacity. This raise funds the team needed to activate those contracts simultaneously and build the execution engine for the next wave of programs.

Seed round

Raising funds in Seed round:

$10M

We have the contracts.
We have the talent.
We're raising to connect the two.

- **Scientific Talent Buildout**
  Close our pipeline of MIT-trained scientists — biologics experts ready to join our commercialization team now. This cohort is available today and won't be indefinitely.
- **Multi-Year Contract Execution**
  Staff the technical teams needed to run parallel customer programs across process development, scale-up modeling, and wet lab validation — simultaneously.
- **Series A Trigger: $2M ARR**
  Every hire directly unlocks contracted revenue. The capital activates existing pipeline, gets us to $2M quality ARR, and positions us for a $12–20M Series A.

josh@bioqore.ai
brendan@bioqore.ai
bioqore.ai

Backed by